



A service of the National Library of Medicine
and the National Institutes of Health

My NCBI
[Sign In] [Register]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed



for

Preview

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

Search	Most Recent Queries	Time	Result
#26	Search (Jablons and dvl-3 or (dvl3))	13:37:29	17
#25	Search Jablons and dvl-3 or (dvl3)	13:28:20	17
#5	Search dvl-3 or (dishevelled-3) or (dishevelled 3) and (cancer or tumor or carcinoma or malignancy) and (inhibitor or antagonist) Limits: Publication Date to 2003/7/31	13:23:40	4
#8	Search (#2 and expression) Limits: Publication Date to 2003/7/31	13:20:57	13
#20	Search (dvl 3) or (dvl-3) and (cancer or carcinoma or tumor or tumour or malignancy) Limits: Publication Date to 2003/7/31	13:19:38	9
#7	Search X2 and expression Limits: Publication Date to 2003/7/31	12:49:59	184
#2	Search dvl-3 or (dishevelled-3) or (dishevelled 3) and (cancer or tumor or carcinoma or malignancy) Limits: Publication Date to 2003/7/31	12:36:20	25
#1	Search dvl-3 or (dishevelled-3) or (dishevelled 3) Limits: Publication Date to 2003/7/31	12:35:33	113

Clear History

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 4 2007 12:47:27

WEST Search History

Inventar
search

DATE: Friday, April 20, 2007

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L5	(jablons)[IN] AND (dishevelled)	6
<input type="checkbox"/>	L4	(xu)[IN] AND (dishevelled)	7
<input type="checkbox"/>	L3	(you)[IN] AND (dishevelled)	6
<input type="checkbox"/>	L2	(he)[IN] AND (disheveled)	4
<input type="checkbox"/>	L1	(he)[IN] AND (dishevelled)	8

END OF SEARCH HISTORY

Welcome to DialogClassic Web(tm)

Dialog level 05.17.01D

Last logoff: 15apr07 13:35:07

Logon file1 20apr07 15:27:25

*** ANNOUNCEMENTS ***

NEW FILES RELEASED

***BIOSIS Previews Archive (File 552)

***BIOSIS Previews 1969-2007 (File 525)

***Engineering Index Backfile (File 988)

***Trademarkscan - South Korea (File 655)

RESUMED UPDATING

***File 141, Reader's Guide Abstracts

RELOADS COMPLETED

***File 5, BIOSIS Previews - archival data added

***Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online

DATABASES REMOVED

Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).

>>>For the latest news about Dialog products, services, content<<<

>>>and events, please visit What's New from Dialog at <<<

>>><http://www.dialog.com/whatsnew/>. You can find news about<<<

>>>a specific database by entering HELP NEWS <file number>.<<<

* * *

File 1:ERIC 1965-2007/Mar

(c) format only 2007 Dialog

Set Items Description

--- -----

Cost is in DialUnits

?

B 155, 159, 10, 203, 35, 5, 467, 73, 434, 34

20apr07 15:28:00 User290558 Session D103.1

\$0.97 0.278 DialUnits File1

\$0.97 Estimated cost File1

\$0.14 INTERNET

\$1.11 Estimated cost this search

\$1.11 Estimated total session cost 0.278 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1950-2007/Apr 13

(c) format only 2007 Dialog

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog

***File 159: Cancerlit is no longer updating.**

Please see HELP NEWS159.

File 10:AGRICOLA 70-2007/Apr

(c) format only 2007 Dialog

File 203:AGRIS 1974-2007/Jan

Dist by NAL, Intl Copr. All rights reserved

File 35:Dissertation Abs Online 1861-2007/Mar

(c) 2007 ProQuest Info&Learning
 File 5: Biosis Previews(R) 1926-2007/Apr W3
 (c) 2007 The Thomson Corporation
***File 5: BIOSIS has been enhanced with archival data. Please see
 HELP NEWS 5 for information.**
 File 467: ExtraMED(tm) 2000/Dec
 (c) 2001 Informania Ltd.
 File 73: EMBASE 1974-2007/Apr 18
 (c) 2007 Elsevier B.V.
 File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 2006 The Thomson Corp
 File 34: SciSearch(R) Cited Ref Sci 1990-2007/Apr W3
 (c) 2007 The Thomson Corp

Set	Items	Description
---	-----	-----

?

S (DVL (W) 3) OR (DISHEVELLED)
 725 DVL
 13077535 3
 41 DVL(W)3
 1798 DISHEVELLED
 S1 1806 (DVL (W) 3) OR (DISHEVELLED)

?

S S1 AND (CANCER OR CARCINOMA OR TUMOR OR TUMUOR OR MALIGNANCY)
 1806 S1
 3683078 CANCER
 1827555 CARCINOMA
 3461327 TUMOR
 58 TUMUOR
 247831 MALIGNANCY
 S2 332 S1 AND (CANCER OR CARCINOMA OR TUMOR OR TUMUOR OR
 MALIGNANCY)

?

S S2 AND (INHIBITOR? OR ANTAGONIST?)
 332 S2
 3281480 INHIBITOR?
 1387386 ANTAGONIST?
 S3 84 S2 AND (INHIBITOR? OR ANTAGONIST?)

?

S S3 AND SIRNA
 84 S3
 21094 SIRNA
 S4 5 S3 AND SIRNA

?

RD S4
 S5 2 RD S4 (unique items)

?

TYPE S5/FULL/1-2

5/9/1 (Item 1 from file: 155)
 DIALOG(R) File 155: MEDLINE(R)
 (c) format only 2007 Dialog. All rts. reserv.

14892738 PMID: 15150100

Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells.

You Liang; He Biao; Uematsu Kazutsugu; Xu Zhidong; Mazieres Julien; Lee Amie; McCormick Frank; Jablons David M

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA.

Cancer research (United States) May 15 2004, 64 (10) p3474-8, ISSN 0008-5472--Print Journal Code: 2984705R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

It is known that Wnt-1 signaling inhibits apoptosis by activating beta-catenin/tcf-mediated transcription. Here, we show that blocking Wnt-1 signaling in beta-catenin-deficient mesothelioma cell lines H28 and MS-1 induces apoptotic cell death. Both Wnt-1 small interfering RNA (siRNA) and Dishevelled siRNA induced significant apoptosis in these cell lines. A small molecule inhibitor of c-Jun NH(2)-terminal kinase inhibited the apoptotic cell killing induced by either Wnt-1 siRNA or Dishevelled siRNA in these cells. Our data suggest that beta-catenin-independent noncanonical pathway(s), i.e., Wnt/JNK pathway, may play a role in the apoptotic inhibition caused by Wnt-1 signaling.

Descriptors: *Apoptosis--physiology--PH; *Cytoskeletal Proteins --deficiency--DF; *Mesothelioma--pathology--PA; *Proto-Oncogene Proteins --antagonists and inhibitors--AI; *Trans-Activators--deficiency--DF; Carcinoma, Non-Small-Cell Lung--genetics--GE; Carcinoma, Non-Small-Cell Lung--pathology--PA; Cytoskeletal Proteins--genetics--GE; Cytoskeletal Proteins--physiology--PH; Humans; Lung Neoplasms--genetics--GE; Lung Neoplasms--pathology--PA; Mesothelioma--genetics--GE; Proto-Oncogene Proteins--physiology--PH; RNA, Small Interfering--administration and dosage --AD; RNA, Small Interfering--genetics--GE; Research Support, Non-U.S. Gov't; Signal Transduction--physiology--PH; Trans-Activators--genetics--GE; Trans-Activators--physiology--PH; Transfection; Wnt Proteins; Wnt1 Protein ; beta Catenin

CAS Registry No.: 0 (CTNNB1 protein, human); 0 (Cytoskeletal Proteins); 0 (Proto-Oncogene Proteins); 0 (RNA, Small Interfering); 0 (Trans-Activators); 0 (WNT1 protein, human); 0 (Wnt Proteins); 0 (Wnt1 Protein); 0 (beta Catenin)

Record Date Created: 20040519

Record Date Completed: 20040802

5/9/2 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

18191819 BIOSIS NO.: 200500097732

Dishevelled promotes neurite outgrowth in neuronal differentiating neuroblastoma 2A cells, via a DIX-domain dependent pathway

AUTHOR: Fan Shongshan; Ramirez Servio H; Garcia Tatiana M; Dewhurst Stephen (Reprint)

AUTHOR ADDRESS: Ctr MedDept Microbiol and Immunol, Univ Rochester, 601

Elmwood Ave, Box 672, Rochester, NY, 14652, USA**USA

AUTHOR E-MAIL ADDRESS: stephendewhurst@urmc.rochester.edu

JOURNAL: Molecular Brain Research 132 (1): p38-50 December 6, 2004 2004

MEDIUM: print

ISSN: 0169-328X _(ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Dishevelled (Dvl) is a cytoplasmic protein involved in the Wnt-Frizzled signaling cascade, which has also been shown to interact with the cytoskeleton in part through inhibition of glycogen synthase kinase 3beta (GSK3beta). Using mouse neuroblastoma 2A (N2A) cells as a model system, we have found that overexpression of Dvl promotes the outgrowth of neurite-like processes, and leads to the induction of a striking, bipolar morphologic phenotype during neuronal differentiation. In contrast, suppression of Dvl expression using isoform-specific siRNAs led to an inhibition of neurite outgrowth in these cells. In order to further elucidate the mechanism(s) responsible for this effect, we overexpressed several mutant forms of Dvl in the N2A cells, including deletions in each of the three major functional subdomains of the protein (DELTA DIX, DELTA PDZ, DELTA DEP) and point mutations in the two well-defined interaction motifs within the DIX domain (the actin-binding and vesicle-association elements; K58A and K68A/E69A, respectively). These experiments revealed that the DIX domain (and its vesicle-binding subregion) was essential for Dvl's effect on neurite extension and morphogenesis in N2A cells. In contrast, direct overexpression of a degradation-resistant form of beta-catenin (S37A), or a dominant negative GSK3beta mutant (K85R), had no effect on neurite outgrowth or morphology in neuronally differentiating N2A cells; exposure of cells to a pharmacologic inhibitor of GSK3 (lithium) also had no effect. Taken together, these results suggest that Dvl induces cytoskeletal and morphologic rearrangements in neuronal differentiating N2A cells through a mechanism that cannot be attributed exclusively to modulation of GSK3beta or beta-catenin activity, but which does depend upon a DIX-domain/vesicle-association-dependent signaling pathway. Copyright 2004 Elsevier B.V. All rights reserved.

REGISTRY NUMBERS: 443900-95-6: glycogen synthase kinase 3 beta

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Molecular Genetics
--Biochemistry and Molecular Biophysics; Nervous System--Neural
Coordination; Tumor Biology

BIOSYSTEMATIC NAMES: Adenoviridae--dsDNA Viruses, Viruses, Microorganisms
; Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: Adenovirus (Adenoviridae)--gene vector; N2A cell line
(Muridae)--morphogenesis

ORGANISMS: PARTS ETC: neuron--nervous system, differentiation, outgrowth

COMMON TAXONOMIC TERMS: Double-Stranded DNA Viruses; Microorganisms;
Viruses; Animals; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman
Mammals; Rodents; Vertebrates

DISEASES: neuroblastoma--neoplastic disease, nervous system disease

MESH TERMS: Neuroblastoma (MeSH)

CHEMICALS & BIOCHEMICALS: beta-catenin--activity; dishevelled--
expression; glycogen synthase kinase 3 beta--activity; siRNA

GENE NAME: N2A cell line GSK3beta gene (Muridae)--mutant

MISCELLANEOUS TERMS: neuritogenesis

CONCEPT CODES:

02506 Cytology - Animal

03502 Genetics - General

03506 Genetics - Animal

10060 Biochemistry studies - General

20504 Nervous system - Physiology and biochemistry

20506 Nervous system - Pathology

24004 Neoplasms - Pathology, clinical aspects and systemic effects

31500 Genetics of bacteria and viruses
 33502 Virology - General and methods
 BIOSYSTEMATIC CODES:
 03116 Adenoviridae
 86375 Muridae

?

Set	Items	Description
S1	1806	(DVL (W) 3) OR (DISHEVELLED)
S2	332	S1 AND (CANCER OR CARCINOMA OR TUMOR OR TUMUOR OR MALIGNANCY)
S3	84	S2 AND (INHIBITOR? OR ANTAGONIST?)
S4	5	S3 AND SIRNA
S5	2	RD S4 (unique items)

?

S S2 AND SIRNA
 332 S2
 21094 SIRNA
 S6 18 S2 AND SIRNA

?

RD S6
 S7 8 RD S6 (unique items)

?

TYPE S7/FULL/1-7

7/9/1 (Item 1 from file: 155)
 DIALOG(R)File 155:MEDLINE(R)
 (c) format only 2007 Dialog. All rts. reserv.

20176129 PMID: 15913453

Efficacy of Wnt-1 monoclonal antibody in sarcoma cells.

Mikami Iwao; You Liang; He Biao; Xu Zhidong; Batra Sonny; Lee Amie Y; Mazieres Julien; Reguart Noemi; Uematsu Kazutsugu; Koizumi Kiyoshi; Jablons David M

Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA. imikami@cc.ucsf.edu

BMC cancer electronic resource (England) 2005, 5 (1) p53, ISSN 1471-2407--Electronic Journal Code: 100967800

Publishing Model Electronic

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

BACKGROUND: Sarcomas are one of the most refractory diseases among malignant tumors. More effective therapies based on an increased understanding of the molecular biology of sarcomas are needed as current forms of therapy remain inadequate. Recently, it has been reported that Wnt-1/beta-catenin signaling inhibits apoptosis in several cancers. In this study, we investigated the efficacy of a monoclonal anti-Wnt-1 antibody in sarcoma cells. **METHODS:** We treated cell lines A-204, SJSA-1, and fresh primary cultures of lung metastasis of sarcoma with a monoclonal anti-Wnt-1 antibody. Wnt-1 siRNA treatment was carried out in A-204. We assessed cell death using Crystal Violet staining. Apoptosis induction was estimated by flow cytometry analysis (Annexin V and PI staining). Cell signaling changes were determined by western blotting analysis. **RESULTS:** We detected Wnt-1

expression in all tissue samples and cell lines. Significant apoptosis induction was found in monoclonal anti-Wnt-1 antibody treated cells compared to control monoclonal antibody treated cells ($p < 0.02$). Similarly, we observed increased apoptosis in Wnt-1 siRNA treated cells. Blockade of Wnt-1 signaling in both experiments was confirmed by analyzing intracellular levels of Dishevelled-3 and of cytosolic beta-catenin. Furthermore, the monoclonal anti-Wnt-1 antibody also induced cell death in fresh primary cultures of metastatic sarcoma in which Wnt-1 signaling was active. CONCLUSION: Our results indicate that Wnt-1 blockade by either monoclonal antibody or siRNA induces cell death in sarcoma cells. These data suggest that Wnt-1 may be a novel therapeutic target for the treatment of a subset of sarcoma cells in which Wnt-1/beta-catenin signaling is active.

Descriptors: *Antibodies, Monoclonal--therapeutic use--TU; *Lung Neoplasms--secondary--SC; *Lung Neoplasms--therapy--TH; *Sarcoma--therapy--TH; *Wnt1 Protein--immunology--IM; Annexin A5--pharmacology--PD; Antibodies, Monoclonal--chemistry--CH; Apoptosis; Blotting, Western; Cell Line, Tumor; Flow Cytometry; Fluorescent Dyes--pharmacology--PD; Gentian Violet--pharmacology--PD; Humans; Lung Neoplasms--immunology--IM; Neoplasm Metastasis; Propidium--pharmacology--PD; Proteins--metabolism--ME; RNA Interference; RNA, Small Interfering--metabolism--ME; Research Support, Non-U.S. Gov't; Sarcoma--embryology--EM; Sarcoma--immunology--IM; Sarcoma--pathology--PA; Signal Transduction; Tumor Cells, Cultured; Wnt1 Protein--chemistry--CH; Wnt1 Protein--physiology--PH; beta Catenin--metabolism--ME

CAS Registry No.: 0 (Annexin A5); 0 (Antibodies, Monoclonal); 0 (DVL3 protein, human); 0 (Fluorescent Dyes); 0 (Proteins); 0 (RNA, Small Interfering); 0 (Wnt1 Protein); 0 (beta Catenin); 36015-30-2 (Propidium); 548-62-9 (Gentian Violet)

Record Date Created: 20050629

Record Date Completed: 20060327

Date of Electronic Publication: 20050524

7/9/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

15575433 PMID: 16007226

Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis.

Mazieres Julien; You Liang; He Biao; Xu Zhidong; Lee Amie Y; Mikami Iwao; McCormick Frank; Jablons David M

UCSF Comprehensive Cancer Center, San Francisco, CA 94115, USA.

Oncogene (England) Aug 11 2005, 24 (34) p5396-400, ISSN 0950-9232--
Print Journal Code: 8711562

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

The Wnt family of secreted glycoproteins is widely involved in cell proliferation, differentiation and oncogenesis. Many Wnt signaling genes are upregulated and activated in chronic lymphocytic leukemia. Less is known concerning acute leukemia. One subtype of acute lymphoblastoid leukemia (ALL) is characterized by a t(1;19) chromosomal translocation resulting in a fusion protein E2A-Pbx1 that promotes transformation and leukemogenesis. Wnt16 has been shown to be targeted by E2A-Pbx1. We performed a differential gene expression array in acute leukemia cell lines

displaying or not displaying the t(1;19) translocation. We found that Wnt16 and many Wnt signaling-related genes were upregulated in the translocation-containing cells. As two isoforms of Wnt16, Wnt16a and Wnt16b, have been recently identified, we demonstrated by using RT-PCR and Western blot that Wnt16b (and not Wnt16a) is overexpressed in t(1;19)-containing cell lines. We then directly addressed the role played by both isoforms in this type of leukemia. Using specific short interfering RNA (siRNA) and an anti-Wnt16 antibody, we showed that targeted-Wnt16b inhibition leads to apoptotic cell death. We also demonstrated that Wnt16b mediates its effect through the canonical Wnt pathway involving dishevelled-2, beta-catenin and survivin. We thus propose that Wnt16 plays an important role in leukemogenesis, raising its therapeutic interest.

Descriptors: *Apoptosis--genetics--GE; *Chromosomes, Human, Pair 1; *Chromosomes, Human, Pair 19; *Glycoproteins--physiology--PH; *Leukemia, Lymphocytic, Acute--genetics--GE; *Leukemia, Lymphocytic, Acute--pathology--PA; *Translocation, Genetic; Gene Expression Profiling; Glycoproteins--biosynthesis--BI; Glycoproteins--genetics--GE; Humans; RNA, Small Interfering; Research Support, Non-U.S. Gov't; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation; Wnt Proteins

CAS Registry No.: 0 (Glycoproteins); 0 (RNA, Small Interfering); 0 (WNT16 protein, human); 0 (Wnt Proteins)

Record Date Created: 20050812

Record Date Completed: 20050901

7/9/3 (Item 3 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

14892738 PMID: 15150100

Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells.

You Liang; He Biao; Uematsu Kazutsugu; Xu Zhidong; Mazieres Julien; Lee Amie; McCormick Frank; Jablons David M

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA.

Cancer research (United States) May 15 2004, 64 (10) p3474-8, ISSN 0008-5472--Print Journal Code: 2984705R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

It is known that Wnt-1 signaling inhibits apoptosis by activating beta-catenin/tcf-mediated transcription. Here, we show that blocking Wnt-1 signaling in beta-catenin-deficient mesothelioma cell lines H28 and MS-1 induces apoptotic cell death. Both Wnt-1 small interfering RNA (siRNA) and Dishevelled siRNA induced significant apoptosis in these cell lines. A small molecule inhibitor of c-Jun NH(2)-terminal kinase inhibited the apoptotic cell killing induced by either Wnt-1 siRNA or Dishevelled siRNA in these cells. Our data suggest that beta-catenin-independent noncanonical pathway(s), i.e., Wnt/JNK pathway, may play a role in the apoptotic inhibition caused by Wnt-1 signaling.

Descriptors: *Apoptosis--physiology--PH; *Cytoskeletal Proteins--deficiency--DF; *Mesothelioma--pathology--PA; *Proto-Oncogene Proteins--antagonists and inhibitors--AI; *Trans-Activators--deficiency--DF; Carcinoma, Non-Small-Cell Lung--genetics--GE; Carcinoma, Non-Small-Cell Lung--pathology--PA; Cytoskeletal Proteins--genetics--GE; Cytoskeletal

Proteins--physiology--PH; Humans; Lung Neoplasms--genetics--GE; Lung Neoplasms--pathology--PA; Mesothelioma--genetics--GE; Proto-Oncogene Proteins--physiology--PH; RNA, Small Interfering--administration and dosage --AD; RNA, Small Interfering--genetics--GE; Research Support, Non-U.S. Gov't; Signal Transduction--physiology--PH; Trans-Activators--genetics--GE; Trans-Activators--physiology--PH; Transfection; Wnt Proteins; Wnt1 Protein; beta Catenin
 CAS Registry No.: 0 (CTNNB1 protein, human); 0 (Cytoskeletal Proteins); 0 (Proto-Oncogene Proteins); 0 (RNA, Small Interfering); 0 (Trans-Activators); 0 (WNT1 protein, human); 0 (Wnt Proteins); 0 (Wnt1 Protein); 0 (beta Catenin)
 Record Date Created: 20040519
 Record Date Completed: 20040802

7/9/4 (Item 4 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2007 Dialog. All rts. reserv.

14537633 PMID: 14562050

Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression.

Uematsu Kazutsugu; He Biao; You Liang; Xu Zhidong; McCormick Frank; Jablons David Mark

Thoracic Oncology Laboratory, UCSF Cancer Center, University of California at San Francisco, San Francisco, CA 94115, USA.

Oncogene (England) Oct 16 2003, 22 (46) p7218-21, ISSN 0950-9232--
 Print Journal Code: 8711562

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

Non small cell lung cancer (NSCLC) is the leading cause of cancer deaths in the United States and worldwide. Unfortunately, standard therapies remain inadequate. An increased understanding of the molecular biology of lung cancer biology is required to develop more effective new therapies. In this report, we show that the Wnt pathway is activated through Dishevelled (Dvl) overexpression in NSCLC. Analysis of freshly resected tumors and lung cancer cell lines demonstrate that Dvl-3, a critical mediator of Wnt signaling, is overexpressed. Specifically, Dvl-3 was overexpressed significantly in 75% of fresh NSCLC microdissected samples compared to control paired matched normal lung samples. To evaluate the biological significance of Wnt signaling and, in particular, Dvl function in lung cancer, we transfected siRNA (designed to inhibit selectively human Dvl-1, -2, and -3), to the NSCLC cell line H1703, which is known to have beta-catenin-mediated Tcf-dependent transcriptional activity. Here, we demonstrate that Dvl-specific siRNA treatment in H1703 decreases significantly Dvl and beta-catenin expression, resulting in reduction of Tcf-dependent transcriptional activity, and, importantly, growth inhibition. Taken together, these data support the novel hypothesis that Dvl overexpression is critical to Wnt signaling activation and cell growth in NSCLC.

Descriptors: *Carcinoma, Non-Small-Cell Lung--genetics--GE; *Gene Expression Regulation, Neoplastic--genetics--GE; *Lung Neoplasms--genetics--GE; *Proto-Oncogene Proteins--genetics--GE; *Zebrafish Proteins; Adenocarcinoma--genetics--GE; Carcinoma, Non-Small-Cell Lung--enzymology --EN; Carcinoma, Squamous Cell--genetics--GE; Humans; Lung Neoplasms --enzymology--EN; Protein-Tyrosine Kinase--genetics--GE; RNA, Small

Interfering--genetics--GE; Tumor Stem Cell Assay; Wnt Proteins

CAS Registry No.: 0 (Proto-Oncogene Proteins); 0 (RNA, Small Interfering); 0 (Wnt Proteins); 0 (Zebrafish Proteins); 0 (wnt8b protein, zebrafish)

Enzyme No.: EC 2.7.1.112 (Protein-Tyrosine Kinase)

Record Date Created: 20031016

Record Date Completed: 20031126

7/9/5 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

18191819 BIOSIS NO.: 200500097732

Dishevelled promotes neurite outgrowth in neuronal differentiating neuroblastoma 2A cells, via a DIX-domain dependent pathway

AUTHOR: Fan Shongshan; Ramirez Servio H; Garcia Tatiana M; Dewhurst Stephen (Reprint)

AUTHOR ADDRESS: Ctr MedDept Microbiol and Immunol, Univ Rochester, 601 Elmwood Ave, Box 672, Rochester, NY, 14652, USA**USA

AUTHOR E-MAIL ADDRESS: stephendewhurst@urmc.rochester.edu

JOURNAL: Molecular Brain Research 132 (1): p38-50 December 6, 2004 2004

MEDIUM: print

ISSN: 0169-328X (ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Dishevelled (Dvl) is a cytoplasmic protein involved in the Wnt-Frizzled signaling cascade, which has also been shown to interact with the cytoskeleton in part through inhibition of glycogen synthase kinase 3beta (GSK3beta). Using mouse neuroblastoma 2A (N2A) cells as a model system, we have found that overexpression of Dvl promotes the outgrowth of neurite-like processes, and leads to the induction of a striking, bipolar morphologic phenotype during neuronal differentiation. In contrast, suppression of Dvl expression using isoform-specific siRNAs led to an inhibition of neurite outgrowth in these cells. In order to further elucidate the mechanism(s) responsible for this effect, we overexpressed several mutant forms of Dvl in the N2A cells, including deletions in each of the three major functional subdomains of the protein (DELTA DIX, DELTA PDZ, DELTA DEP) and point mutations in the two well-defined interaction motifs within the DIX domain (the actin-binding and vesicle-association elements; K58A and K68A/E69A, respectively). These experiments revealed that the DIX domain (and its vesicle-binding subregion) was essential for Dvl's effect on neurite extension and morphogenesis in N2A cells. In contrast, direct overexpression of a degradation-resistant form of beta-catenin (S37A), or a dominant negative GSK3beta mutant (K85R), had no effect on neurite outgrowth or morphology in neuronally differentiating N2A cells; exposure of cells to a pharmacologic inhibitor of GSK3 (lithium) also had no effect. Taken together, these results suggest that Dvl induces cytoskeletal and morphologic rearrangements in neuronal differentiating N2A cells through a mechanism that cannot be attributed exclusively to modulation of GSK3beta or beta-catenin activity, but which does depend upon a DIX-domain/vesicle-association-dependent signaling pathway. Copyright 2004 Elsevier B.V. All rights reserved.

REGISTRY NUMBERS: 443900-95-6: glycogen synthase kinase 3 beta

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Molecular Genetics

--Biochemistry and Molecular Biophysics; Nervous System--Neural
Coordination; Tumor Biology
BIOSYSTEMATIC NAMES: Adenoviridae--dsDNA Viruses, Viruses, Microorganisms
; Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia
ORGANISMS: Adenovirus (Adenoviridae)--gene vector; N2A cell line
(Muridae)--morphogenesis
ORGANISMS: PARTS ETC: neuron--nervous system, differentiation, outgrowth
COMMON TAXONOMIC TERMS: Double-Stranded DNA Viruses; Microorganisms;
Viruses; Animals; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman
Mammals; Rodents; Vertebrates
DISEASES: neuroblastoma--neoplastic disease, nervous system disease
MESH TERMS: Neuroblastoma (MeSH)
CHEMICALS & BIOCHEMICALS: beta-catenin--activity; dishevelled--
expression; glycogen synthase kinase 3 beta--activity; siRNA
GENE NAME: N2A cell line GSK3beta gene (Muridae)--mutant
MISCELLANEOUS TERMS: neuritogenesis
CONCEPT CODES:
02506 Cytology - Animal
03502 Genetics - General
03506 Genetics - Animal
10060 Biochemistry studies - General
20504 Nervous system - Physiology and biochemistry
20506 Nervous system - Pathology
24004 Neoplasms - Pathology, clinical aspects and systemic effects
31500 Genetics of bacteria and viruses
33502 Virology - General and methods
BIOSYSTEMATIC CODES:
03116 Adenoviridae
86375 Muridae

7/9/6 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17950389 BIOSIS NO.: 200400321146
**Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt
signaling pathway**
AUTHOR: Maye Peter; Zheng Jie; Li n; Wu Dianqing (Reprint)
AUTHOR ADDRESS: Ctr HlthDept Genet and Dev Biol, Univ Connecticut,
MC3301,263 Farmington Ave, Farmington, CT, 06030, USA**USA
AUTHOR E-MAIL ADDRESS: dwu@neuron.uchc.edu
JOURNAL: Journal of Biological Chemistry 279 (23): p24659-24665 June 4,
2004 2004
MEDIUM: print
ISSN: 0021-9258
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The effect of a noncanonical Wnt, Wnt11, on canonical Wnt
signaling stimulated by Wnt1 and activated forms of LRP5 (low density
lipoprotein receptor-related protein-5), Dishevelled1 (Dvl1), and
beta-catenin was examined in NIH3T3 cells and P19 embryonic carcinoma
cells. Wnt11 repressed Wnt1-mediated activation of LEF-1 reporter
activity in both cell lines. However, Wnt11 was unable to inhibit
canonical signaling activated by LRP5, Dvl1, or beta-catenin in NIH3T3
cells, although it could in P19 cells. In addition, Wnt11-mediated
inhibition of canonical signaling in NIH3T3 cells is ligand-specific;
Wnt11 could effectively repress canonical signaling activated by Wnt1,

Wnt3, or Wnt3a but not by Wnt7a or Wnt7b. Co-culture experiments with NIH3T3 cells showed that the co-expression of Wnt11 with Wnt1 was not an essential requirement for the inhibition, suggesting receptor competition as a possible mechanism. Moreover, in both cell types, elevation of intracellular Ca²⁺ levels, which can result from Wnt11 treatment, led to the inhibition of canonical signaling. This result suggests that Wnt11 might not be able to signal in NIH3T3. Furthermore, P19 cells were found to express both endogenous canonical Wnts and Wnt11. Knockdown of Wnt11 expression using siRNA resulted in increased LEF-1 reporter activity, thus indicating that Wnt11-mediated suppression of canonical signaling exists in vivo.

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Cell Biology

BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: NIH3T3 cell line (Muridae)--murine fibroblast cells; P19 cell line (Muridae)--murine embryonic carcinoma cells

COMMON TAXONOMIC TERMS: Animals; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman Mammals; Rodents; Vertebrates

CHEMICALS & BIOCHEMICALS: Dvl1 {Dishevelled 1}; Wnt1; Wnt11; Wnt3; Wnt3a; Wnt7a; beta-catenin; low-density lipoprotein; low-density lipoprotein receptor; low-density lipoprotein receptor-related protein-5

MISCELLANEOUS TERMS: canonical Wnt signaling pathway--multiple Wnt11-mediated repression mechanisms

CONCEPT CODES:

02502 Cytology - General

02506 Cytology - Animal

10060 Biochemistry studies - General

10064 Biochemistry studies - Proteins, peptides and amino acids

10066 Biochemistry studies - Lipids

BIOSYSTEMATIC CODES:

86375 Muridae

7/9/7 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

13390056 EMBASE No: 2005467061

Efficacy on Wnt-1 monoclonal antibody in sarcoma cells

Mikami I.; You L.; He B.; Xu Z.; Batra S.; Lee A.Y.; Mazieres J.; Reguart N.; Uematsu K.; Koizumi K.; Jablons D.M.

Dr. D.M. Jablons, Department of Surgery, Comprehensive Cancer Center, 1600 Divisadero St., San Francisco, CA 94115 United States

AUTHOR EMAIL: jablonsd@surgery.ucsf.edu

BMC Cancer (BMC CANCER) (United Kingdom) 24 MAY 2005, 5/- (7p)

CODEN: BCMAC ISSN: 1471-2407

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 21

Background: Sarcomas are one of the most refractory diseases among malignant tumors. More effective therapies based on an increased understanding of the molecular biology of sarcomas are needed as current forms of therapy remain inadequate. Recently, it has been reported that Wnt-1/beta-catenin signaling inhibits apoptosis in several cancers. In this study, we investigated the efficacy of a monoclonal anti-Wnt-1 antibody in sarcoma cells. Methods: We treated cell lines A-204, SJSA-1, and fresh

primary cultures of lung metastasis of sarcoma with a monoclonal anti-Wnt-1 antibody. Wnt-1 siRNA treatment was carried out in A-204. We assessed cell death using Crystal Violet staining. Apoptosis induction was estimated by flow cytometry analysis (Annexin V and PI staining). Cell signaling changes were determined by western blotting analysis. Results: We detected Wnt-1 expression in all tissue samples and cell lines. Significant apoptosis induction was found in monoclonal anti-Wnt-1 antibody treated cells compared to control monoclonal antibody treated cells ($p < 0.02$). Similarly, we observed increased apoptosis in Wnt-1 siRNA treated cells. Blockade of Wnt-1 signaling in both experiments was confirmed by analyzing intracellular levels of Dishevelled-3 and of cytosolic beta-catenin. Furthermore, the monoclonal anti-Wnt-1 antibody also induced cell death in fresh primary cultures of metastatic sarcoma in which Wnt-1 signaling was active. Conclusions: Our results indicate that Wnt-1 blockade by either monoclonal antibody or siRNA induces cell death in sarcoma cells. These data suggest that Wnt-1 may be a novel therapeutic target for the treatment of a subset of sarcoma cells in which Wnt-1/beta-catenin signaling is active. (c) 2005 Mikami et al; licensee BioMed Central Ltd.

DRUG DESCRIPTORS:

*monoclonal antibody--pharmacology--pd
small interfering RNA; Wnt1 protein--endogenous compound--ec; beta catenin
--endogenous compound--ec; unclassified drug

MEDICAL DESCRIPTORS:

*sarcoma cell
drug efficacy; cancer cell culture; lung metastasis; apoptosis; flow
cytometry; Western blotting; protein expression; signal transduction; human
; controlled study; human tissue; human cell; article

DRUG TERMS (UNCONTROLLED): Wnt1 protein antibody--pharmacology--pd

SECTION HEADINGS:

016 Cancer
030 Clinical and Experimental Pharmacology
037 Drug Literature Index

?

Set	Items	Description
S1	1806	(DVL (W) 3) OR (DISHEVELLED)
S2	332	S1 AND (CANCER OR CARCINOMA OR TUMOR OR TUMUOR OR MALIGNANCY)
S3	84	S2 AND (INHIBITOR? OR ANTAGONIST?)
S4	5	S3 AND SIRNA
S5	2	RD S4 (unique items)
S6	18	S2 AND SIRNA
S7	8	RD S6 (unique items)
?		

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 8 JAN 29 PHAR reloaded with new search and display fields
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13 FEB 26 MEDLINE reloaded with enhancements
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19 MAR 16 CASREACT coverage extended
NEWS 20 MAR 20 MARPAT now updated daily
NEWS 21 MAR 22 LWPI reloaded
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 23 MAR 30 INPADOCDB will replace INPADOC on STN
NEWS 24 APR 02 JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:40:01 ON 20 APR 2007

```
=> file caplus, bioeng, biotechno, biotechds, esbiobase
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                      ENTRY      SESSION
FULL ESTIMATED COST                0.21          0.21
```

```
FILE 'CAPLUS' ENTERED AT 16:40:36 ON 20 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE 'BIOENG' ENTERED AT 16:40:36 ON 20 APR 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)
```

```
FILE 'BIOTECHNO' ENTERED AT 16:40:36 ON 20 APR 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.
```

```
FILE 'BIOTECHDS' ENTERED AT 16:40:36 ON 20 APR 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION
```

```
FILE 'ESBIOBASE' ENTERED AT 16:40:36 ON 20 APR 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.
```

```
=> s (dvl-3) or dishevelled
L1      1059 (DVL-3) OR DISHEVELLED
```

```
=> s L1 and (antagonist or inhibitor)
L2      165 L1 AND (ANTAGONIST OR INHIBITOR)
```

```
=> s L2 and (cancer or tumor or tumuot or carcinoma or malignancy)
L3      62 L2 AND (CANCER OR TUMOR OR TUMUOT OR CARCINOMA OR MALIGNANCY)
```

```
=> s L3 and sirna
L4      2 L3 AND SIRNA
```

```
=> duplicate remove l4
DUPLICATE PREFERENCE IS 'CAPLUS, ESBIOBASE'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L4
L5      2 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)
```

```
=> d l5 bib abs 1-2
```

```
L5      ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
AN      2007:113586  CAPLUS
DN      146:226597
TI      Gene expression profiles in esophageal cancer and their use in
        diagnosis, prognosis, therapy and drug design and selection
IN      Nakamura, Yusuke; Daigo, Yataro; Nakatsuru, Shuichi
PA      Oncotherapy Science, Inc., Japan; The University of Tokyo
SO      PCT Int. Appl., 249pp.
        CODEN: PIXXD2
DT      Patent
LA      English
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007013671	A2	20070201	WO 2006-JP315342	20060726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRAI US 2005-703263P P 20050727

AB In order to identify the mols. involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Addnl., genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate mol. target genes, a Homo sapiens epithelial cell transforming sequence 2 oncogene (ECT2) and a cell division cycle 45, *S. cerevisiae*, homolog-like (CDC45L) are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target mols. for esophageal cancer. Furthermore, the present inventors have identified DKK1 as a potential biomarker for diagnosis of cancer such as lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. DKK1 was specifically over-expressed in most lung and esophageal cancer tissues the present inventors examined, and was elevated in the sera of a large proportion of patients with these tumors. DKK1, combined with other tumor markers, could significantly improve the sensitivity of cancer diagnosis. Moreover, this mol. is also a likely candidate for development of therapeutic approaches such as antibody therapy.

L5 ANSWER 2 OF 2 Elsevier BIOBASE COPYRIGHT 2007 Elsevier Science B.V. on STN

AN 2004136202 ESBIOBASE

TI Inhibition of Wnt-1 signaling induces apoptosis in β -catenin-deficient mesothelioma cells

AU You L.; He B.; Uematsu K.; Xu Z.; Mazieres J.; Lee A.; McCormick F.; Jablons D.M.

CS D.M. Jablons, Department of Surgery, Cancer Center, Box 1674, 1600 Divisadero Street, San Francisco, CA 94115, United States.
E-mail: jablonsd@surgery.ucsf.edu

SO Cancer Research, (15 MAY 2004), 64/10 (3474-3478), 33 reference(s)
CODEN: CNREA8 ISSN: 0008-5472

DT Journal; Article

CY United States

LA English

SL English

AB It is known that Wnt-1 signaling inhibits apoptosis by activating β -catenin/tcf-mediated transcription. Here, we show that blocking Wnt-1 signaling in β -catenin-deficient mesothelioma cell lines H28 and MS-1 induces apoptotic cell death. Both Wnt-1 small interfering RNA (siRNA) and Dishevelled siRNA induced significant apoptosis in these cell lines. A small molecule inhibitor of c-Jun NH.sub.2-terminal kinase inhibited the apoptotic cell killing induced by either Wnt-1 siRNA or Dishevelled siRNA in these cells. Our data suggest that β -catenin-independent noncanonical pathway(s), i.e., Wnt/JNK pathway, may play a role in the apoptotic inhibition caused by Wnt-1 signaling.

=> ds

DS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

WEST Search History

DATE: Friday, April 20, 2007

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L9	L1 and siRNA	14
<input type="checkbox"/>	L8	L4 and expression and siRNA and cancer	13
<input type="checkbox"/>	L7	L4 and expression and siRNA	14
<input type="checkbox"/>	L6	L4 and (lung and mesothelioma and breast) and expression	6
<input type="checkbox"/>	L5	L4 and (lung and mesothelioma and breast)	6
<input type="checkbox"/>	L4	L2 and (inhibitor or antagonist)	52
<input type="checkbox"/>	L3	L2 and (inhibitor or antagnoist)	52
<input type="checkbox"/>	L2	L1 and (cancer or tumor or carcinoma or malignancy)	54
<input type="checkbox"/>	L1	(dvl-3) or (dvl3)	57

END OF SEARCH HISTORY